Table 3.
Clinical studies demonstrating efficacy of palmitoylethanolamidea.
| Pathology | References |
|---|---|
| Non-surgical lumbar radiculopathies | Chirchiglia et al., 2018 |
| Chronic pain (including neuropathic pain) of differing etiologies | Skaper et al., 2014; Paladini et al., 2016 |
| Endometriosis | Iuvone et al., 2016; Indraccolo et al., 2017 |
| Fibromyalgia | Del Giorno et al., 2015 |
| Parkinson disease (adjuvant therapy) | Brotini et al., 2017 |
| Relapsing-remitting multiple sclerosis (add-on therapy for the treatment of interferon-β1a-related adverse effects) | Orefice et al., 2016 |
| Stroke (adjuvant therapy) | Caltagirone et al., 2016 |
| Amyotrophic lateral sclerosis | Clemente, 2012; Palma et al., 2016 |
| Autism | Antonucci et al., 2015; Bertolino et al., 2017 |
a
micronized/ultramicronized palmitoylethanolamide.